• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Biomol Struct Dyn. Online ahead of print. Discovery of Potential Multi-Target-Directed Ligands by Targeting Host-specific SARS-CoV-2 Structurally C

tetano

Editor, Senior Moderator
J Biomol Struct Dyn. 2020 Apr 24;1-16.
doi: 10.1080/07391102.2020.1760137. Online ahead of print.
Discovery of Potential Multi-Target-Directed Ligands by Targeting Host-specific SARS-CoV-2 Structurally Conserved Main Protease [SUP]$[/SUP]


Rakesh S Joshi[SUP] 1 2 [/SUP], Shounak S Jagdale[SUP] 1 [/SUP], Sneha B Bansode[SUP] 1 [/SUP], S Shiva Shankar[SUP] 1 2 [/SUP], Meenakshi B Tellis[SUP] 1 3 [/SUP], Vaibhav Kumar Pandya[SUP] 1 [/SUP], Anita Chugh[SUP] 4 [/SUP], Ashok P Giri[SUP] 1 2 [/SUP], Mahesh J Kulkarni[SUP] 1 2 [/SUP]



Affiliations

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in the current COVID-19 pandemic. Worldwide this disease has infected over 2.5 million individuals with a mortality rate ranging from 5 to 10%. There are several efforts are going on in the drug discovery to control the SARS-CoV-2 viral infection. The main protease (M[SUP]Pro[/SUP]) plays a critical role in viral replication and maturation, thus can serve as the primary drug target. To understand the structural evolution of M[SUP]Pro[/SUP], we have performed phylogenetic and Sequence Similarity Network analysis, that depicted divergence of Coronaviridae M[SUP]Pro[/SUP] in five clusters specific to viral hosts. This clustering was corroborated with the comparison of M[SUP]Pro[/SUP] structures. Furthermore, it has been observed that backbone and binding site conformations are conserved despite variation in some of the residues. These attributes can be exploited to repurpose available viral protease inhibitors against SARS-CoV-2 M[SUP]Pro[/SUP]. In agreement with this, we performed screening of ∼7100 molecules including active ingredients present in the Ayurvedic anti-tussive medicines, anti-viral phytochemicals and synthetic anti-virals against SARS-CoV-2 M[SUP]Pro[/SUP] as the primary target. We identified several natural molecules like δ-viniferin, myricitrin, taiwanhomoflavone A, lactucopicrin 15-oxalate, nympholide A, afzelin, biorobin, hesperidin and phyllaemblicin B that strongly binds to SARS-CoV-2 M[SUP]Pro[/SUP]. Intrestingly, these molecules also showed strong binding with other potential targets of SARS-CoV-2 infection like viral receptor human angiotensin-converting enzyme 2 (hACE-2) and RNA dependent RNA polymerase (RdRp). We anticipate that our approach for identification of multi-target-directed ligand will provide new avenues for drug discovery against SARS-CoV-2 infection.
 
Back
Top Bottom